Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
Por:
Dohner, H, Wei, AH, Appelbaum, FR, Craddock, C, DiNardo, CD, Dombret, H, Ebert, BL, Fenaux, P, Godley, LA, Hasserjian, RP, Larson, RA, Levine, RL, Miyazaki, Y, Niederwieser, D, Ossenkoppele, G, Rollig, C, Sierra, J, Stein, EM, Tallman, MS, Tien, HF, Wang, JX, Wierzbowska, A, Lowenberg, B
Publicada:
22 sep 2022
Resumen:
The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.
Filiaciones:
Dohner, H:
Ulm Univ Hosp, Dept Internal Med 3, Ulm, Germany
Wei, AH:
Royal Melbourne Hosp, Dept Haematol, Peter MacCallum Canc Ctr, Melbourne, Australia
Univ Melbourne, Melbourne, Australia
Appelbaum, FR:
Univ Washington, Seattle, WA USA
Fred Hutchinson Canc Res Ctr, Seattle, WA USA
Craddock, C:
Univ Birminham, Queen Elizabeth Hosp, Ctr Clin Haematol, Birmingham, England
DiNardo, CD:
Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX USA
Dombret, H:
Univ Paris, Hop St Louis, Assistance Publ Hop Paris, Dept Hematol,St Louis Inst Res, Paris, France
Ebert, BL:
Dana Farber Canc Inst, Boston, MA USA
Fenaux, P:
Hop St Louis, Assistance Publ Hop Paris, Serv Hematol Seniors, Paris, France
Godley, LA:
Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL USA
Hasserjian, RP:
Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA
Larson, RA:
Univ Chicago, Dept Med, Chicago, IL USA
Univ Chicago, Comprehens Canc Ctr, Chicago, IL USA
Levine, RL:
Mem Sloan Kettering Canc Ctr, Dept Med, Human Oncol & Pathogenesis Program, New York, NY USA
Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA
Miyazaki, Y:
Nagasaki Univ, Atom Bomb Dis Inst, Dept Hematol, Nagasaki, Japan
Niederwieser, D:
Univ Leipzig, Leipzig, Germany
Ossenkoppele, G:
Amsterdam UMC, Locat VU Univ Med Ctr, Dept Haematol, Amsterdam, Netherlands
Rollig, C:
Tech Univ Dresden, Dept Internal Med 1, Univ Hosp Carl Gustav Carus, Dresden, Germany
Sierra, J:
Hosp Santa Creu & Sant Pau, Hematol Dept, Barcelona, Spain
Stein, EM:
Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA
Tallman, MS:
Mem Sloan Kettering Canc Ctr, Dept Med, Leukemia Serv, New York, NY USA
Tien, HF:
Natl Taiwan Univ Hosp, Dept Internal Med, Div Hematol, Taipei, Taiwan
Wang, JX:
Chinese Acad Med Sci & Peking Union Med Coll, Inst Hematol, Tianjin, Peoples R China
Chinese Acad Med Sci & Peking Union Med Coll, Blood Dis Hosp, Tianjin, Peoples R China
Wierzbowska, A:
Med Univ Lodz, Dept Hematol, Lodz, Poland
Lowenberg, B:
Erasmus MC, Dept Hematol, Rotterdam, Netherlands
Erasmus MC Canc Inst, Rotterdam, Netherlands
hybrid, All Open Access; Hybrid Gold
|